AstraZeneca Gets EU Approval for Qtern to Treat Type 2 Diabetes
July 19 2016 - 10:03AM
Dow Jones News
By Rory Gallivan
LONDON--AstraZeneca PLC (AZN.LN) said Tuesday the European Union
has approved its Qtern tablets for the treatment of type 2 diabetes
in all 28 EU member countries and Iceland, Lichtenstein and
Norway.
"Nearly half of all people with type 2 diabetes are unable to
reach their treatment goal and so risk developing complications due
to hyperglycaemia, said Elisabeth Bjork, vice president, head of
cardiovascular and metabolic diseases, global medicines development
at AstraZeneca.
"Qtern is the first combination product of its kind approved in
Europe and an important new treatment option to help patients reach
their goals through powerful HbA1c reduction," she added.
At 1318 GMT, AstraZeneca's shares were up 7 pence, or 0.2%, at
4,536 pence, valuing the company at GBP57.4 billion ($76
billion).
Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
(END) Dow Jones Newswires
July 19, 2016 09:48 ET (13:48 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
